The first PBS listing of a CGRP inhibitor for migraine prevention is a game-changer for a condition with a huge health and economic burden in Australia. Last night a panel of experts discussed the pathophysiology of CGRP and headache, the development of CGRP targeting drugs and the practical applications of the treatments currently available. Watch ...
Watch on demand: Preventative migraine therapy in Australia: defining the role of CGRP therapy
9 Jun 2021